相关实验视频

Updated: May 24, 2025

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery

Published on: July 18, 2019

通过向长非编码RNAINCR1来改善质母细胞瘤中的IL12免疫疗法

Shikha Saini¹, Josephina A M A Gadet^1,2, Gordon J Freeman³

¹Harvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 02115, USA.

Journal of neuro-oncology

|March 4, 2025

概括

沉默长非编码RNAINCR1通过减少免疫抑制基因,比PD-L1抑制更有效地增强质母细胞瘤的介质素12 (IL12) 基因疗法. 这种方法可能会改善IL12治疗在GBM中的疗效.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
基因治疗基因治疗

背景情况:

质母细胞瘤 (GBM) 具有高度的免疫抑制作用,限制了IL12基因治疗的疗效.
免疫检查点PD-1/PD-L1的上调进一步阻碍了抗瘤反应.
以前的IL12和PD-1/PD-L1抑制剂的联合疗法表现出有限的成功.

研究的目的:

研究长非编码RNAINCR1在GBM免疫抑制中的作用.
评估INCR1沉默与IL12基因疗法结合的疗效.
为了比较INCR1沉默与PD-L1抑制在克服GBM的免疫抑制微环境.

主要方法:

在使用RNAscope进行IL12治疗前和后的GBM患者组织中分析INCR1和PD-L1表达.
评估了通过qPCR与IL12刺激的免疫细胞共同培养的患者衍生的GBM细胞中的免疫抑制基因表达.
通过RNA测序和3D细胞毒性测定,评估了对免疫抑制途径的基因沉默效应.

主要成果:

在GBM组织中,IL12基因治疗上调了INCR1和PD-L1.
与PD-L1沉默相比,INCR1沉默显示出多个免疫抑制基因的优异减少.
沉默INCR1增强了IL12介导的免疫细胞抗瘤活性,比PD-1/PD-L1阻断更有效.

结论:

与PD-L1.1相比,INCR1沉默的目标是更多的免疫逃避途径.
准INCR1是一个有希望的策略,可以增强IL12基因治疗质母细胞瘤的效果.
在GBM免疫疗法中,INCR1抑制可以克服抵抗机制.

关键词:

在INCR1中,可以使用INCR1.在GBMGBMGBMGBMGBM 在 IL12 中, IL12 是 IL12 的代名词.免疫治疗是一种免疫疗法.在PD-L1中.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...